Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PMA Panel Asks TherOx For New Data On Cath-Lab-Based Oxygen Therapy

This article was originally published in The Gray Sheet

Executive Summary

FDA's Circulatory System Devices advisory panel is encouraging TherOx to sponsor a new clinical trial of its SSO2 SuperSaturated Oxygen Therapy Downstream system to demonstrate the therapy improves clinical outcomes in heart attack patients

You may also be interested in...

Market Intel: Heart Attack Therapy Firms Seek Unobstructed Path For MVO Solutions

When it comes to treating acute heart attack patients, primary percutaneous coronary intervention (PPCI) remains the gold standard of care. And while this life-saving procedure restores blood flow through the coronary artery, perfusion in all areas of the heart may not occur. In this article, we'll highlight three innovative medtech companies that have developed very different solutions to try to improve upon the current standard of care and hear perspectives from interventional cardiologists.

Research In Brief

Research news on hip replacements, a spinal cord stimulator and more.

Bayesian Gets A Boost With Guidance, But Technique Still Not For Everyone

The complex calculations of Bayesian statistics are not likely to become standard for FDA device submissions anytime soon, but they could help streamline clinical trials in many more instances, CDRH's top statistics official says

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts